# GLP-3 RTA > Source: https://chooseunscripted.com/peptide/glp-3-rta/ > Content type: Peptide research profile > Last updated: September 4, 2026 **For research use only. Not for human or veterinary use.** ## Scientific / Common Name GLP-3 RTA ## Alternative Names / Synonyms Retatrutide · LY3437943 · LY-3437943 ## Molecular Formula C₂₂₁H₃₄₂N₄₆O₆₈ ## Molecular Weight 4731.33 g/mol ## CAS Number 2381089-83-2 ## Clinical Development Phase Phase 3 ## Peptide Classification GIP, GLP-1, and glucagon receptor triple agonist ## Primary Research Focus Obesity and body-weight regulation; type 2 diabetes and glycemic control; cardiovascular and renal outcomes; metabolic dysfunction-associated steatotic liver disease (MASLD); obstructive sleep apnea; and obesity-associated musculoskeletal conditions. ## Mechanism Summary **GLP-3 RTA corresponds to retatrutide, an investigational peptide engineered to activate three metabolically relevant receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor.** Retatrutide’s activity at the GIP and GLP-1 receptors is associated with pathways involved in glucose-dependent insulin secretion, appetite regulation, and energy intake. Its additional glucagon receptor activity distinguishes it from single- and dual-receptor incretin agonists and is being investigated for its potential effects on energy expenditure and metabolic regulation. The compound’s biological activity reflects the combined effects of these three receptor pathways rather than the action of any single receptor in isolation. The relative contribution of each receptor pathway to observed clinical outcomes remains an active area of investigation. ## Evidence Summary Retatrutide has been evaluated across Phase 2 and Phase 3 clinical trials investigating obesity, type 2 diabetes, and related cardiometabolic conditions. In a randomized Phase 2 trial involving **338 adults with obesity or overweight plus a weight-related condition**, retatrutide produced dose-dependent reductions in body weight over 48 weeks. Participants receiving the **12 mg dose had a mean body-weight reduction of 24.2% at week 48**, compared with **2.1% with placebo**. More recent Phase 3 results have expanded the evidence base. In **TRIUMPH-1**, participants receiving 12 mg retatrutide lost an average of **28.3% of body weight at 80 weeks**. In **TRIUMPH-2**, adults with obesity or overweight and type 2 diabetes receiving 12 mg lost an average of **20.8% at 80 weeks**, with A1C reductions of up to **1.6 percentage points**. Results have also been reported from additional Phase 3 studies evaluating retatrutide across obesity and related cardiometabolic conditions. Retatrutide remains **investigational and is not approved by any regulatory agency**. Additional Phase 3 studies are ongoing across obesity, type 2 diabetes, cardiovascular and renal outcomes, metabolic dysfunction-associated steatotic liver disease (MASLD), and other obesity-related conditions. ## Key References **Jastreboff AM, Kaplan LM, Frías JP, et al.** [Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972) *New England Journal of Medicine.* 2023;389:514–526. **Eli Lilly and Company.** [What to Know About Retatrutide](https://www.lilly.com/news/stories/what-to-know-about-retatrutide) Updated July 2026. **Eli Lilly and Company.** [TRIUMPH-1 Phase 3 Results](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss) May 21, 2026. **Eli Lilly and Company.** [TRIUMPH-2 and TRIUMPH-3 Phase 3 Results](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional) July 23, 2026. ## Last Scientifically Reviewed August 9, 2026 ## Quick Definition GLP-3 RTA is a research compound corresponding to retatrutide, an investigational triple receptor agonist that targets the GIP, GLP-1, and glucagon receptor pathways. Retatrutide is being investigated clinically for its effects on metabolic regulation, body weight, and related cardiometabolic outcomes. ## Regulatory Status INVESTIGATIONAL · NOT FDA APPROVED ## Targets / Receptors GIP receptor (GIPR); GLP-1 receptor (GLP-1R); glucagon receptor (GCGR) ## Safety & Limitations Retatrutide remains investigational, and its safety and efficacy continue to be evaluated in clinical trials. In the Phase 2 obesity trial, the most commonly reported adverse events were gastrointestinal and were generally mild to moderate in severity. Gastrointestinal events were dose-related and were partially mitigated by use of a lower starting dose. Dose-dependent increases in heart rate were also observed, peaking at 24 weeks and declining thereafter. Results from clinical trials should not be interpreted as establishing safety or efficacy for uses that have not received regulatory approval. Retatrutide has not been approved by any regulatory agency and is not currently available for public use. ## Frequently Asked Questions - ### What is GLP-3 RTA? GLP-3 RTA is a research compound corresponding to retatrutide, an investigational peptide that acts as a triple agonist at the GIP, GLP-1, and glucagon receptors. Retatrutide is being studied clinically for its effects on metabolic regulation, body weight, and related cardiometabolic outcomes. - ### Is GLP-3 RTA the same as retatrutide? GLP-3 RTA corresponds to the compound identified in the scientific literature as retatrutide, also known by the development code LY3437943. Published clinical studies and trial records generally use the name retatrutide rather than GLP-3 RTA. - ### How does GLP-3 RTA work? The compound activates three receptor pathways involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor. This triple-receptor activity distinguishes retatrutide from compounds that target only GLP-1 or the combined GIP and GLP-1 pathways. - ### Has GLP-3 RTA been studied in humans? The corresponding investigational compound, retatrutide, has been evaluated in human clinical trials, including Phase 2 studies and an ongoing Phase 3 development program. Clinical research should be interpreted using the specific formulations, doses, populations, and pro - ### Is GLP-3 RTA FDA approved? No. Retatrutide remains investigational and is not FDA approved. GLP-3 RTA is intended for research use only and should not be represented as an approved therapeutic product. ## Product URL ## Multi-Compound Blend No ## Available Research Compound - [Product page](https://chooseunscripted.com/shop/glp-3-rta/index.md)